NAD+ Therapy, NMN, and NR: What the Evidence Shows

NAD+ therapy sits at the intersection of real biology, supplement marketing, clinical research, and longevity medicine.

The biology isn't imaginary. NAD+ stands for nicotinamide adenine dinucleotide, a coenzyme cells use in energy metabolism, redox reactions, DNA-repair pathways, and stress-response systems. It's part of cellular work, not a vague wellness concept.

The protocol question is more specific: what happens when a person tries to raise NAD+ through oral precursors such as NMN or NR, through IV NAD+, or through a clinic-led protocol?

That's where the evidence has to stay organized. Raising a blood NAD+ biomarker, feeling better day to day, improving a disease-specific outcome, changing a healthspan marker, and slowing aging are different claims. They deserve different evidence standards.

What NAD+ Is

NAD+ is a coenzyme. It isn't a peptide, hormone, stimulant, or vitamin in the way most people use those words.

Cells use NAD+ to move electrons during energy production and to support enzymes involved in DNA repair, metabolic signaling, inflammation, and cellular stress response. Some of those pathways consume NAD+ as they work.

That's why NAD+ became a longevity story. If NAD+ availability falls during aging, disease, inflammation, metabolic stress, infection, or other high-demand states, then supporting NAD+ could plausibly matter. The better version of the idea is not that every healthy person needs more NAD+ all the time. It is that NAD+ support may matter most when the biology or clinical target is defined ¹⁴.

That's the distinction worth holding onto.

NMN, NR, and IV NAD+ Are Not the Same Thing

The NAD+ category often gets discussed as if every product is interchangeable. It isn't.

NMN stands for nicotinamide mononucleotide. NR stands for nicotinamide riboside. Both are oral NAD+ precursors, meaning the body can use them as raw material to make NAD+ through related pathways.

IV NAD+ is different. It delivers NAD+ by infusion. Evidence from oral NMN or NR trials shouldn't be automatically transferred to IV NAD+ wellness claims.

There's also a pharmaceutical-development lane. Some NAD+ compounds are being studied as investigational drugs for defined diseases. That can be meaningful research, but it isn't the same thing as proof that a supplement slows aging in healthy adults.

What Oral NMN and NR Reliably Do

The strongest claim for oral NMN and NR is straightforward: they can raise circulating NAD+ in humans.

In a randomized clinical trial of nicotinamide riboside chloride, oral NR at 100, 300, and 1,000 mg per day for eight weeks raised whole-blood NAD+ in a dose-responsive pattern ¹.

Head-to-head human data also show that oral NR and NMN can both raise circulating NAD+ at research doses. A 2026 Nature Metabolism study compared NAD+ boosters in healthy adults and found that NMN and NR both affected circulating NAD+ and microbial metabolism ².

That matters. A biomarker that reliably moves isn't nothing.

It's also not the whole ladder. A higher blood NAD+ level doesn't automatically prove tissue-level repletion, better mitochondrial function, slower biological aging, lower disease risk, better fitness, or longer life.

The practical move is to ask what kind of claim is being made:

• Is the claim that NAD+ went up?
• Is the claim that symptoms improved?
• Is the claim that a disease-specific outcome improved?
• Is the claim that healthspan improved?
• Is the claim that aging slowed?

Each step needs stronger evidence than the one before it.

Where Human Outcome Signals Are Strongest

The most compelling human signals come from defined populations, not from broad healthy-aging claims.

Werner syndrome is the clearest example. It's a rare genetic disorder associated with accelerated-aging biology. In a randomized crossover trial, nicotinamide riboside supplementation in people with Werner syndrome produced clinically meaningful signals across several organ-level measures ⁵. That's a strong result, and its strength comes from the population: a rare condition with severe biological stress and NAD+ relevance.

Metabolic stress is another important lane. In postmenopausal women with prediabetes, NMN improved muscle insulin sensitivity and insulin-stimulated glucose disposal in a controlled trial ⁶. That doesn't mean NMN becomes a general weight-loss or glucose-optimization product for everyone. It means a defined metabolic population moved on a defined metabolic endpoint.

Peripheral artery disease gives a functional example. The NICE randomized clinical trial studied nicotinamide riboside in people with peripheral artery disease, where walking distance is clinically meaningful. It reported improvement in six-minute walk distance, with adherence shaping the size of the effect ⁷.

There's also a vascular subgroup signal from a study of healthy middle-aged and older adults taking NR. The full cohort matters, but the more interesting signal appeared in people with elevated baseline blood pressure, where blood pressure and vascular measures moved more meaningfully ⁸.

The pattern matters. NAD+ protocols look most compelling when the target is specific: a depleted or stressed biology, a disease population, a metabolic endpoint, or a functional measure.

What Healthy-Adult Trials Have and Have Not Shown

Healthy-adult NAD+ claims need a more measured interpretation.

A 2026 PRISMA-guided systematic review pulled together preclinical and clinical evidence for NAD+ supplementation in anti-aging and wellness contexts. The authors found that NAD+ precursors can raise NAD+ and are generally well tolerated, but effects on functional, metabolic, vascular, and other outcomes were mixed and endpoint-specific ³.

That's the difference between a mechanism and a health outcome.

The older-adult muscle literature is also sobering. A 2025 systematic review and meta-analysis of NMN and NR trials in older adults found no significant improvement in skeletal muscle mass or function outcomes such as handgrip strength and gait speed ⁴.

At the animal-lifespan level, the evidence also has boundaries. In the NIH Interventions Testing Program, nicotinamide riboside didn't extend lifespan in genetically heterogeneous UM-HET3 mice ⁹. That doesn't settle every NAD+ question, but it does keep lifespan claims from getting ahead of the evidence.

That doesn't make NAD+ protocols useless. It means healthy-aging claims should be specific.

Many people report better energy, sleep, or recovery while using NMN, NR, or NAD+ protocols. That belongs in the wellspan category: how someone feels and functions day to day. It shouldn't be dismissed. It also shouldn't be treated as the same thing as a placebo-controlled clinical outcome unless the trial measured and confirmed it.

For longevity medicine, the honest framing is practical: NAD+ protocols can be considered, but the plan should name the target before interpreting the result.

NMN vs. NR

NMN and NR sit close together in the NAD+ pathway. Both support NAD+ synthesis, and both have human data showing NAD+ biomarker movement.

The comparison comes up often, usually because people already have a side picked. The better comparison is practical: which molecule has evidence for the outcome you care about?

NR has several clinical-trial anchors, including the dose-response biomarker trial, peripheral artery disease research, Parkinson's disease safety and cerebral NAD+ work, and the Werner syndrome trial ^{1 5 7 10 11}.

NMN has notable metabolic-stress evidence in prediabetes and a separate investigational drug-development lane through MIB-626, a pharmaceutical-grade NMN program being studied for defined diseases ^{6 13}.

At the practical level, neither molecule should be treated as universally superior. Compare:

• the reason for using it;
• the dose and duration studied;
• whether the evidence measured a biomarker, symptom, or clinical outcome;
• the population studied;
• tolerability and medication context;
• product quality and regulatory status;
• whether a clinician is helping interpret the protocol.

If the aim is simply to raise NAD+, both NMN and NR have evidence. For a clinical outcome, the specific trial population matters more than the brand argument.

IV NAD+ Therapy

IV NAD+ is visible in longevity clinics, wellness centers, and recovery services. It deserves its own lane.

The main issue is route. IV NAD+ isn't the same intervention as oral NMN or NR. A study showing that oral NR raises NAD+ doesn't prove that IV NAD+ improves aging, recovery, fatigue, brain health, or cellular repair.

That doesn't mean IV NAD+ can never be part of a clinician's protocol. It means the evidence standard should be clear. A clinic-led infusion protocol should explain what problem it's treating, what evidence supports that route, what monitoring is used, and what would count as a meaningful response.

For now, IV NAD+ anti-aging and wellness claims remain more debated than oral NAD+ precursor biomarker claims.

Safety, Side Effects, and Regulatory Status

Short-term oral NR and NMN trial data are generally reassuring, but that doesn't mean the category is risk-free.

NR has been studied at high doses in short clinical contexts. In the NR-SAFE trial, people with Parkinson's disease received high-dose nicotinamide riboside over four weeks, with the study focused on safety and tolerability ¹⁰. That's useful safety context, especially because it involved a medically relevant population.

Long-term safety is less complete. Most supplement trials run weeks to months, not years. That matters for a product category many people take indefinitely.

Cancer questions also require careful language. Some tumor cells depend on NAD+ metabolism, which is why researchers raise cancer context as a mechanistic question. Human trials haven't established that NAD+ precursor supplementation causes cancer in healthy adults. The right conclusion isn't certainty in either direction. It's clinical context, especially for people with active cancer, prior cancer, unexplained symptoms, or complex medical history.

Regulatory status is also part of the decision. NMN has had a complicated U.S. regulatory history tied to dietary-supplement rules, new dietary ingredient filings, and drug-development activity. That history is about market access and regulatory category, not proof that NMN works or doesn't work clinically ¹².

For any NAD+ protocol, quality matters. Know the exact compound, how it is taken or infused, where it comes from, why you are using it, and when the plan gets reviewed before making it part of a longer routine.

How to Evaluate a NAD+ Protocol

A stronger NAD+ protocol starts by naming the target.

If the target is a biomarker, the plan should decide whether blood NAD+ testing is worth doing, how often it would be repeated, and what change would matter.

If the target is wellspan, the plan should define the experience being tracked: energy, sleep, recovery, exercise tolerance, brain fog, or fatigue. Subjective outcomes can be meaningful, but they should be tracked consistently rather than remembered selectively.

If the target is metabolic risk, the plan should include baseline and follow-up markers such as glucose, insulin context when appropriate, A1C, lipids, blood pressure, liver markers, body composition, and symptoms.

If the target is a disease-specific question, the protocol belongs in clinical care. Werner syndrome, peripheral artery disease, Parkinson's disease, prediabetes, chronic kidney disease, neurodegenerative disease, and cancer context aren't do-it-yourself longevity categories.

1. 1
   Name the target

   Decide whether the protocol is aimed at NAD+ level, symptoms, metabolic stress, function, or disease-specific care.
2. 2
   Match the evidence

   Use established evidence for biomarker claims, emerging evidence for defined populations, and more caution for broad anti-aging or IV wellness claims.
3. 3
   Track the response

   Choose the marker, symptom, functional measure, or clinical outcome before starting so the protocol can be adjusted.
4. 4
   Know when to stop or change

   A protocol should have a review point for side effects, lack of benefit, abnormal labs, cost, medication changes, or new symptoms.

A baseline-first approach helps here. Blood biomarkers can show whether metabolic, inflammatory, liver, kidney, or cardiovascular markers are part of the target. Biological age testing can help place aging-score claims in context, though those scores shouldn't be treated as proof that a NAD+ protocol works. Executive physicals can be useful when a person wants a team to interpret the whole picture.

Where Provider-Guided Care Matters

Provider guidance matters when the NAD+ protocol is connected to medical conditions, medications, abnormal labs, neurologic disease, cancer history, metabolic disease, cardiovascular disease, kidney disease, pregnancy planning, severe fatigue, or IV therapy.

It also matters when a person is using multiple protocols at once. NAD+ often appears beside GLP-1s, hormone therapy, peptides, supplements, sleep interventions, exercise changes, and aggressive diagnostics. The more moving parts there are, the more interpretation matters.

A clinician or clinic can help answer practical questions:

• Is the target clear enough to justify the protocol?
• Does the person's medical history change the risk?
• Are there medications or conditions that need review?
• What baseline labs or symptoms should be checked?
• What response would count as meaningful?
• When should the protocol be stopped, changed, or escalated?

NAD+ therapy is most useful when it's treated as a targeted protocol rather than a general anti-aging reflex. Oral NMN and NR can move the biomarker. Defined human signals exist. IV NAD+ needs its own evidence standard. The best next step is to match the route, target, and follow-up plan before deciding what belongs in a longevity program.